- Why Cryoport
- Who We Serve
- About Us
- News & Events
- Investor Relations
- Contact Us
Are your advanced therapy supply chains ready for this year’s 4G/LTE data management transition?
A leap forward in standardizing the regenerative medicine supply chain
Date: November 25-26, 2022
Location: Bruges, Belgium
Date: December 5-8, 2022
Location: Amsterdam, The Netherlands
Companies vying to be the first to market with breakthrough treatments have a great deal riding on the success of their efforts. Incorporating innovative processes, ethical considerations, assuring the safety and efficacy of the product, and managing the commodity's environmental control are formidable challenges that often lack standardized quality control procedures. Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. The fragility of regenerative medicine therapies and the need to manage risk means a fourth link in the chain will soon be a regulatory requirement.
Many biopharmaceutical companies, academic institutions, and manufacturing sites often need to move their valuable life-saving therapies and research materials locally for a variety of reasons, such as lab relocation or drug product administration on the patient. Local shipments require just as much care and attention as any long-distance transport, and Cryoport Systems has created a specialized solution to mitigate risk even further for those local deliveries. Cryoport owns and operates an in-house fleet of shuttles, Cryoshuttle®, which provides convenient and personalized local pickup and delivery service in select geographical regions that are in proximity to Cryoport Systems’ Global Logistics and Supply Chain Centers. We are proudly serving the Southern California area including Los Angeles, Orange County and San Diego, the Houston Metropolitan Area in Texas, New York City Metro and New Jersey, as well as internationally around Amsterdam, The Netherlands.